To the full analysis
Pharmanutra stock: growth
PHN.MIPharmanutra reported $145.92M in revenue for fiscal 2025, up 13.4% on the prior year, up 17.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
17.5%
per year from 2015 to 2025, per share 13.8%
Earnings (Annual rate)
22.8%
per year from 2015 to 2025, per share 18.9%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | |
|---|---|---|
| Revenue | 17.6% | 17.5% |
| Revenue per share | 17.9% | 13.8% |
| Earnings | 7.3% | 22.8% |
| Earnings per share | 7.6% | 18.9% |
| Free cash flow | 9.4% | no data |
| Free cash flow per share | 9.7% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2015 | $29.09M | $2.85M | $0 |
| 2016 | $36.57M | $4.27M | $4.09M |
| 2017 | $41.87M | $6.68M | $5.29M |
| 2018 | $51.72M | $9.48M | $6.25M |
| 2019 | $59.63M | $9.37M | $7.89M |
| 2020 | $64.8M | $15.59M | $11.59M |
| 2021 | $75.51M | $15.26M | $17.09M |
| 2022 | $92.41M | $16.67M | −$9.63M |
| 2023 | $111.96M | $14.22M | −$1.28M |
| 2024 | $128.7M | $18.4M | $18.01M |
| 2025 | $145.92M | $22.16M | $18.2M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.